Mucosal cytokine therapy: Marked antiviral and antitumor activity

Journal of Interferon and Cytokine Research

Volumn 19, Issue 8, 1999, Pages 911-921

  Tovey, Michael G ^a,b   Meritet, Jean François ^a   Guymarho, Jacqueline ^a   Maury, Chantal ^a  

^a Laboratory of Viral Oncology   (France)

^b Laboratory of Viral Oncology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOKINE; INTERLEUKIN 18; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALOMYOCARDITIS VIRUS; ERYTHROLEUKEMIA CELL; FEMALE; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FRIEND MURINE LEUKEMIA VIRUS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERONS; INTERLEUKINS; LETHAL DOSE 50; LEUKEMIA, EXPERIMENTAL; MICE; MUCOUS MEMBRANE; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; SURVIVAL RATE; VIRUS DISEASES; VIRUS REPLICATION;

ANIMALIA; ENCEPHALOMYOCARDITIS VIRUS;

EID: 0032838743     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313451     Document Type: Article

References (30)

1. NEGRIER, S., ESCUDIER, B., LASSET, C., DOUILLARD, J-Y., SAVARY, J., CHEVREAU, C., RAVAUD, A., MERCATELLO, A., PENY, J., MOUSSEAU, M., PHILIP, T., and TURSZ, T. (1998). Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. New Engl. J. Med. 338, 1272-1278.
2. ROSENBERG, S.A., YANG, J.C., TOPALIAN, S.L., SCHWARTZENTRUBER, D.J., WEBER, J.S., PARKINSON, D.R., SEIPP, CA., EINHORN, J.H., and WHITE, D.E. (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc. 271, 907-913.
3. KAKUMU, S., FUJI, A., YOSHIOKA, K., et al. (1988). Pilot study of recombinant human interleukin 2 for chronic type B hepatitis. Hepatology 8, 487-492.
4. HOOFNAGLE, J.H., and DI BISCEGLIE, A.M. (1997). The treatment of chronic viral hepatitis. New Engl. J. Med. 336, 347-356.
5. GUTTERMAN, J.U. (1994). Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA 91, 1198-1205.
6. ARANY, I., and TYRING, S.K. (1996). Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J. Interferon Cytokine Res. 16, 453-460.
7. BELARDELLI, F., and GRESSER, I. (1996). The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17, 369-372.
8. BEILHARZ, M.W., McDONALD, W., WATSON, M.W., HENG, J., McGEACHIE, J., and LAWSON, C.M. (1997). Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res. 17, 625-630.
9. KAIDO, T.J. (1997). Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases. J. Interferon Cytokine Res. 17, 31-36.
10. TOVEY, M.G., and MAURY, C. (1999). Oromucosal interferon therapy: marked antiviral and antitumor activity. J. Interferon Cytokine Res. 19, 145-155.
11. EID, P., MERITET, J-F., MAURY, C., LASFAR, A., WEILL, D., and TOVEY, M.G. (1999). Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. J. Interferon Cytokine Res. 19, 157-169.
12. GRESSER, I., TOVEY, M.G., BANDU, M-T., MAURY, C., and BROUTY-BOYE, D. (1916). Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144, 1305-1315.
13. MOGENSEN, K.E., PYHÄLÄ, L., and CANTELL, K. (1975). Raising antibodies to human leukocyte interferon. Acta Pathol. Microbiol. Scand. Sect. B. Microbiol. Immunol. 83, 443.
14. GRESSER, I., BOURALI, C., THOMAS, M-T., and FALCOFF, E. (1968). Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus. Proc. Soc. Exp. Biol. Med. 127, 491-196.
15. TOVEY, M.G., BEGON-LOURS, J., and GRESSER, I. (1974). A method for the large scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809-815.
16. AFFABRIS, E., JEMMA, C., and ROSSI, G.B. (1982). Isolation of interferon-resistant variants of Friend erythroleukemia cells: effect of interferon and ouabain. Virology 120, 441-452.
17. ASANUMA, H., INABA, Y., AIZAWA, C., KURATA, T., and TAMURA, S-I. (1995). Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. J. Immunol. Methods 187, 41-51.
18. REUKART, R.R. (1985). Picornoviruses and their replication. In: Virology. N.B. Fields (ed.) New York: Raven Press, pp. 705-738.
19. MÜLLER, U., STEINHOFF, U., REIS, L.F.L., HEMMI, S., PAVLOVIC, J., ZINKERNAGEL, R.M., and AGUET, M. (1994). Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921.
20. MOSMANN, T.R., and SAD, S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146.
21. TSAI, S.L., LIAW, Y.F., CHEN, M.H., HUANG, C.Y., and KUO, G.C. (1997). Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25, 449-458.
22. WALDMANN, T.A. (1993). The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol. Today 14, 264-270.
23. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., LOUDON, R., SHERMAN, F., PERUSSIA, B., and TINCHIERI, G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845.
24. KENNEDY, M.K., and PARK, L.S. (1996). Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J. Clin. Immunol. 16, 134-143.
25. OKAMURA, H., TSUTSI, H., KOMATSU, T., YUTSUDO, M., HAKURA, A., TANIMOTO, T., TORIGOE, K., OKURA, T., NUKADA, Y., and HATTORI, K. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378, 88-91.
26. SPINOZZI, F., AGEA, E., BISTONI, O., FORENZA, N., and BERTOTTO, A. (1998). γδ T cells, allergen recognition and airway inflammation. Immunol. Today 19, 22-26.
27. WALKER, W.A., and ISSELBACHER, K.J. (1974). Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders. Gastroenterology 67, 531-550.
28. BAYLEY, D., TEMPLE, C., CLAY, V., STEWARD, A., and LOWTHER, N. (1995). The transmucosal absorption of recombinant human interferon-α B/D hybrid in the rat and rabbit. J. Pharm. Pharmacol. 47, 721-724.
29. MACHIDA, M. SANO, K., ARAKAWA, M., HAYASHI, M., and AWAZU, S. (1993). Absorption of recombinant human granulocyte colony-stimulating factor (rhG-GSF) from rat nasal mucosa. Pharmaceutical Res. 10, 1372-1377.
30. KOREN, S., and FLEISCHMANN, Jr., W.R. (1994). Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2. J. Interferon Res. 14, 343-347.